Skip to main content

Advertisement

Table 3 Objective response rates for over all population and subgroups of patients

From: Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

  N Overall response rate (%) Clinical benefit rate (%) Median PFS (95%CI), months
Overall 32 43.8 56.3 8.3 (7.1–9.4)
Hormone receptor status
 HR(−) 12 33.3 41.7 5.5 (0–11.5)
 HR(+) 20 50 65 8.8 (6.46–11.0)
No. of prior chemotherapy
 0 22 50 54.5 8.8 (7.4–10.1)
 1 10 30 70 8.3 (3.7–12.8)
Metastatic site
 Visceral 23 43.5 60.9 8.3 (7.2–9.3)
 Non-visceral 9 44.4 44.4 9.0 (4.2–13.8)
Dose reduction during treatment
 No reduction 18 33.3 50 8.8 (3.9–13.6)
 Reduction 14 57.1 64.3 8.3 (7.8–8.7)
Hormone receptor status
 Triple negative 11 36.4 36.4 5.5 (1.3–9.7)
 Other 21 47.6 71.4 8.8 (7.0–10.5)